Commercialization of monoclonal antibodies may be the biotechnology success story of the 1980s. While most products of genetic engineering are still characterized as having potential or hypothetical commercial applications, there are at least 30 monoclonal antibody-based products on the market now. Hybritech, a California biotechnology firm, leads the field in production and marketing of new applications for monoclonal antibodies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Prescott, L. Hybritech: Portrait of a Monoclonal Specialist. Nat Biotechnol 1, 156–161 (1983). https://doi.org/10.1038/nbt0483-156
Issue Date:
DOI: https://doi.org/10.1038/nbt0483-156